Detalhe da pesquisa
1.
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Gastroenterology
; 152(1): 164-175.e4, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720838
2.
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Hepatology
; 65(2): 439-450, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27770561
3.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
; 165(9): 625-634, 2016 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537841
4.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727022
5.
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
J Hepatol
; 61(2): 200-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24747798
6.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
; 145(5): 1035-1044.e5, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924660
7.
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lancet Infect Dis
; 23(9): 1007-1019, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348519
8.
Safety and Immunogenicity of a 100 µg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
medRxiv
; 2022 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35291289
9.
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Nat Med
; 28(5): 1042-1049, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241844
10.
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Nat Med
; 28(11): 2388-2397, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36202997
11.
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
Clin Ther
; 40(5): 704-718.e6, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703432
12.
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
Lancet Gastroenterol Hepatol
; 2(11): 814-823, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802814
13.
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Lancet Gastroenterol Hepatol
; 2(11): 805-813, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802816